Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 614.13Cr 548.67Cr 503.98Cr 457.72Cr 859.56Cr 58TCr 881.16Cr 6.02TCr 2.42TCr 31TCr 2.31TCr 2.26TCr 97TCr P/E 2026 *
95.8x
P/E 2027 * 35.9x
Enterprise Value 614.13Cr 548.67Cr 503.98Cr 457.72Cr 859.56Cr 58TCr 881.16Cr 6.02TCr 2.42TCr 31TCr 2.31TCr 2.26TCr 97TCr EV / Sales 2026 *
21.1x
EV / Sales 2027 * 16.1x
Free-Float
97.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.64%
1 week+0.60%
Current month-2.83%
1 month+2.23%
3 months+7.38%
6 months+37.33%
Current year+65.87%
1 week 306.17
Extreme 306.17
325.96
1 month 281.74
Extreme 281.7401
325.96
Current year 175.89
Extreme 175.89
326.63
1 year 175.89
Extreme 175.89
326.63
3 years 51.21
Extreme 51.21
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Exercice

General Counsel

5,680 0.0285%
22/09/26 Tax

Director

-115 0.0006%
10/09/26 Sell

Director

-1,200 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%+0.60%+63.99%+480.86% 614.13Cr
+0.77%+10.74%+58.34%+150.01% 1,25700Cr
-1.17%-0.54%+43.50%+76.61% 65TCr
-0.14%+0.58%+35.89%+103.68% 51TCr
-1.56%-2.01%+50.67%+64.81% 39TCr
-2.38%+1.98%+75.34%+39.91% 37TCr
-0.02%+2.11%+32.16%+57.79% 30TCr
-0.72%+7.32%+11.29%+33.98% 29TCr
-0.41%+3.47%+56.43%+71.76% 25TCr
-0.36%+6.56%+38.89%+107.77% 21TCr
Average -0.30%+4.09%+46.65%+118.72% 42.33TCr
Weighted average by Cap. -0.41%+5.29%+47.96%+95.01%

Financials

2026 *2027 *
Net sales 29Cr 26Cr 24Cr 22Cr 41Cr 2.76TCr 42Cr 285.4Cr 114.81Cr 1.46TCr 109.36Cr 107.02Cr 4.62TCr 38Cr 34Cr 31Cr 28Cr 53Cr 3.61TCr 55Cr 373.22Cr 150.14Cr 1.9TCr 143.01Cr 139.95Cr 6.04TCr
Net income 6.12Cr 5.47Cr 5.02Cr 4.56Cr 8.56Cr 579.62Cr 8.78Cr 60Cr 24Cr 305.92Cr 23Cr 22Cr 969.65Cr 19Cr 17Cr 16Cr 14Cr 27Cr 1.81TCr 27Cr 187.59Cr 75Cr 957.48Cr 72Cr 70Cr 3.03TCr
Net Debt - -
Projected Income Statement - Annual - Ligand Pharmaceuticals Incorporated
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
03/26/03 $313.61 +2.14% 60,709
02/26/02 $307.02 -4.87% 2,65,434
30/26/30 $322.75 +1.71% 3,44,311
29/26/29 $317.33 -0.45% 2,99,391
28/26/28 $318.78 +2.26% 2,68,467
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ligand Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
307.02USD
Average target price
350.92USD
Spread / Average Target
+14.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ligand Pharmaceuticals Incorporated
  1. Stock Market
  2. Stocks
  3. LGND Stock